Top Stories

Tacconi moves back to Merck to head investigational obesity drug

July 25, 2007

Merck has brought back consumer marketing guru Len Tacconi to serve as global brand leader for its lead investigational component for obesity, taranabant.
 

Panel votes to keep Avandia on the market with tougher label

July 31, 2007

Federal advisors recommended keeping GlaxoSmithKlines embattled type 2 diabetes drug Avandia on the market but said its label should include strict warnings on use.
 

Are you making as much as other healthcare marketers?

July 31, 2007

Come to think of it, do pharma companies pay better than agencies? And is there still a gender gap? Which sectors and positions are the most satisfying to work in? Please take a moment to complete the 21st MM&M Career & Salary Survey and help us to provide you and the rest of the industry with the most accurate and meaningful picture of salaries, aspirations, motivation, job satisfaction and trends in the job market.
 

In Other News

J&J plans to cut workforce by up to 4%

July 31, 2007

Johnson Johnson said today it would reduce its 120,500-member global work force by 3% to 4%, or as many as 4,800 jobs, through attrition and hiring freezes.
 

Synova seeks to stage a comeback with the Today Sponge

July 31, 2007

It was a plot point on a famous episode of Seinfeld, but that was the high point for the Today Sponge in recent years. Now, 12 years after Wyeth stopped making it, a new owner is looking to relaunch the contraceptive sponge to a highly-segmented swatch of consumers with brighter packaging, print ads and a Web site.
 

Merck taps its top lawyer to oversee global sales and marketing orgs

July 26, 2007

Merck has selected its top lawyer, Kenneth Frazier, to oversee its worldwide sales and marketing organizations as EVP, global human health, beginning Aug. 1
 

Analyst: S-P addicted to cholesterol pills

July 26, 2007

Strong sales of cholesterol drugs helped Schering-Plough post a twofold increase in quarterly profit this week, but earnings may expose an over-reliance on Vytorin and Zetia.
 

Internet most trusted source for health info: survey

July 30, 2007

Seventy-five percent of consumers consider the Internet their most trusted source for researching drug information, a new survey shows.
 

Sponsored Links

Extend Your Reach with About.com Health

About.com Health delivers a robust audience of 7 million uniques each month who come for relevant health information in more than 80 in-depth topic areas. About.com Health delivers a high quality audience: a high concentration of women between the ages of 25-54 - higher than other health web sites - and an audience that goes online more frequently for health information. To reach this healthy audience, contact Michael Frick at mfrick@about.com or find out more at humanexperience.about.com.

In Other News

Januvia, Singulair, Advair top sites among primary care docs: study

July 25, 2007

Web sites for Mercks Type 2 diabetes drug Januvia, Mercks asthma and allergy treatment Singulair and GlaxoSmithKlines asthma medication Advair were the top three online product destinations respectively among US primary care doctors in 2007, a new study shows.
 

GlaxoSmithKline, Ranbaxy settle Valtrex patent dispute

July 27, 2007

Generics drug firm Ranbaxy Laboratories said it has reached an agreement with GlaxoSmithKline resulting in a dismissal of US patent litigation regarding Glaxos herpes pill Valtrex (valacyclovir hydrochloride).
 

Advisory panel OKs Evista to reduce breast cancer risk

July 25, 2007

An FDA advisory panel voted to back Eli Lillys request to tell patients its osteoporosis treatment Evista (raloxifene) also helps reduce the risk of breast cancer, despite concerns over the drugs cardiovascular side effects.
 

AstraZeneca slashes jobs, Euro sales and marketing posts impacted

July 26, 2007

AstraZeneca said it plans to eliminate an additional 4,600 jobs in Europe and North America as part of a major cost-cutting initiative aimed at helping save the company $900 million by 2010.
 

Zelnorm to re-enter market through restricted access program

July 27, 2007

The FDA has agreed to permit limited use of Novartis Zelnorm (tegaserod maleate) by some patients through a restricted access program, following the drugs voluntary withdrawal over cardiovascular safety concerns earlier this year.
 

Product news

July 31, 2007

Vivius has received FDA approval for the marketing of Evamist, a metered dose transdermal estradiol spray for the treatment of moderate to severe vasomotor symptoms due to menopause.
 

People news

July 31, 2007

Peregrine Pharmaceuticals, a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, appointed Mary Boyd as head of business development for Asia and Europe.
 

Company news

July 31, 2007

Merck has agreed to purchase San Diego-based NovaCardia, a privately held clinical-stage pharmaceutical company focused on cardiovascular diseases, for $350 million plus the amount of cash on hand at the time of closing.
 



Advertise
For details on how to advertise in MM&M News Brief, please email Doreen Gates

Unsubscribe
To unsubscribe from the MM&M News Brief click here.
To manage your entire MM&M profile login to your account.

You are subscribed as: %%EMAIL%%

To contact Haymarket Media for general questions or unsubscribe problems, please reply to this email.

All MM&M newsletters are sent from the domain "email.mmm-online.com". When configuring e-mail or spam
filter rules, please use this domain name.

Medical Marketing & Media Magazine
114 W. 26th Street 4th Floor
New York N.Y. 10001
Phone: (646) 638-6000
Fax: (646) 638-6150
http://www.mmm-online.com/

© 2013 Haymarket Media Inc.